Neurology · Parkinson's DiseaseRegulatory Approvalregulatorymid-term

FDA Grants AP Status for Amantadine Hydrochloride ANDA210215

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/16/2026, 12:32:49 AM

Assessment confidence: 63% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Amantadine Hydrochloride for POM Pharma represents a significant regulatory milestone that could reshape competitive dynamics in the Parkinson's Disease treatment landscape. Pharma strategy teams must closely monitor the implications of this approval on market positioning and competitive strategies. Regulatory context from FDA (FDA AP — AMANTADINE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 25 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market dynamics and consider strategies to maintain competitive advantage. The strongest clinical anchor is A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Parkinson's Disease, 8 regulatory and 4 competitive items passed relevance filtering for POM Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy. This approval could enhance POM Pharma's position in the market for Parkinson's Disease treatments, potentially increasing competition against existing therapies.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — AMANTADINE HYDROCHLORIDE (SUPPL) (FDA). Entity match (pom pharma); Regulatory pathway relevance (nda). The approval signifies a successful regulatory pathway for POM Pharma, which may encourage further submissions in the neurology therapeutic area and influence future regulatory strategies.

Key Risks

Elevated medium regulatory exposure for POM Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

POM Pharma's entry into the market with Amantadine Hydrochloride may disrupt existing market shares and compel other companies to adjust their strategies, potentially affecting revenue streams.
Lead sponsor: Bausch & Lomb Incorporated.
Portfolio teams should assess the impact of this approval on market dynamics and consider strategies to maintain competitive advantage.

What Would Change This Assessment

This becomes more urgent if Monitor the launch timeline and market entry strategies of POM Pharma for Amantadine Hydrochloride.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — AMANTADINE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (pom pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SOTALOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ALFUZOSIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VERAPAMIL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Genetic Studies of Chronic Active Epstein-Barr Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
LASER VERSUS CRYSTALLIZED PHENOL IN PILONIDAL SINUS DISEASE
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study Evaluating the Safety and Efficacy of Fixed-Dose Combination for Dry Eye Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for ZERBAXA Supplement by Cubist Pharmaceuticals
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for OCREVUS Supplemental Application
Humanexa Signalsmedium relevance
Moderate corpus alignment

RNA polymerase II phosphorylation dynamics: from molecular mechanisms to human disease.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lactiplantibacillus plantarum (WJL) ameliorates chronic kidney disease by inhibiting fibroblast growth factor 21 adaptive stress response via low protein diet.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sweet cherry pomace polyphenols disrupt Salmonella enteritidis colonization on chicken skin.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Green synthesis of ZnO nanoparticles using pomegranate husk extract: comparative evaluation of antioxidant, enzyme inhibition, and cytotoxic properties.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

POM Pharma
Amantadine Hydrochloride
Parkinson's Disease market

Commercial impact

medium

POM Pharma's entry into the market with Amantadine Hydrochloride may disrupt existing market shares and compel other companies to adjust their strategies, potentially affecting revenue streams.

Regulatory impact

medium

The approval signifies a successful regulatory pathway for POM Pharma, which may encourage further submissions in the neurology therapeutic area and influence future regulatory strategies.

What to watch

Monitor the launch timeline and market entry strategies of POM Pharma for Amantadine Hydrochloride.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.